Latest Articles and Analysis

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

Potential harms of state PDABs on HIV treatment access and ending the epidemic.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

2024 federal healthcare policy priorities: 340B reform, PBM oversight, and telehealth.

PDABs and upper-payment limits risk restricting medication access despite affordability intentions.

$100 billion 340B program lacks patient accountability; reform needed for charitable care obligations.

PDAB state implementation variations and how patients can engage in the process.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Introduction to PDABs: structure, function, and importance for patient medication access.

340B reform must prioritize patients: charity care obligations and medical debt reduction.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.